UK-based ViaNautis raises $25M for its next-gen drug delivery platform — TFN

ViaNautis, a Cambridge-based nanomedicine company, has secured $25 million in Series A funding led by 4BIO Capital, BGF, and UCB Ventures. The investment will be used to advance the company's proprietary drug delivery platform, polyNaut®, develop new products using this technology, expand its teams, and establish new lab facilities. ViaNautis was spun out of UCL in 2018 and is focused on exploiting the unique capabilities of polyNaut®, a nano-engineered polymer technology designed for targeted intracellular delivery.

ViaNautis Raises $25 Million for Next-Gen Drug Delivery Platform

ViaNautis is a Cambridge-based nanomedicine company spun out of UCL in 2018. The company's mission is to exploit the unique capabilities of the revolutionary polyNaut® technology, a versatile nano-engineered polymer technology designed for targeted intracellular delivery. This technology enables polymer nanoparticles to deliver a wide range of payloads from small molecules to genetic materials, creating a bionic nanoparticle. It enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm.

A Cambridge-based nanomedicine company specializing in targeted intracellular drug delivery using the polyNaut® technology.

2 years ago

ViaNautis Raises $25 Million for Next-Gen Drug Delivery Platform

Covered on